Blog
  by

In the News: October 5–11

CMS Releases Lookup Tool for Advanced APM Participants

CMS unveiled an interactive lookup tool where clinicians participating in Advanced Alternative Payment Models (APMs) can obtain their Qualifying APM Participant (QP) status. Under MACRA’s Quality Payment Program, clinicians who are identified as QPs based on the 2017 performance year will receive a Medicare incentive payment in 2019 and are exempt from the Merit-based Incentive Payment System (MIPS) quality reporting program for the 2017 performance year. QP determinations are now available for the first QP snapshot period (ie, claims between January 1 and March 31, 2017).

Clinicians that are not identified as QPs should review whether they are subject to the MIPS quality reporting program for the 2017 performance year through the MIPS Participation lookup tool. To learn more about MACRA’s Quality Payment Program, read the Sg2 Special Report—MACRA: Answers, Impact and Strategic Imperatives, which offers our answers to your frequently asked questions on MACRA.


Sepsis Initiatives May Increase Clostridium Difficile Rates

A recent study in the American Journal of Infection Control found that sepsis treatment protocols may cause unintended effects. Researchers determined that antibiotic use and hospital-acquired Clostridium difficile infection rates increased after implementation of sepsis initiatives. While these initiatives are intended to improve patient outcomes, study authors concluded that more research is needed to better understand the implications of infectious disease guidelines and protocols.

As hospitals and health systems explore innovative ways to mitigate risks associated with hospital-acquired infections, it has become increasingly important for administrators to evaluate these approaches and their impact on patient care. To learn more about hospital-acquired infections, check out the Sg2 post, Antibiotic-Resistant Pathogens: More than a Bug, Potential Business Chaos.


GAO Releases Study on Neonatal Abstinence Syndrome

In response to the nearly five-fold increase in the number of babies born with neonatal abstinence syndrome (NAS) between 2000 and 2012, the Government Accountability Office (GAO) conducted a study to examine NAS in the US and Medicaid-covered treatment. The GAO report “1) describes the hospital and nonhospital settings for treating infants with NAS and how Medicaid pays for services; 2) describes recommended practices and challenges for addressing NAS; and 3) examines [the US Department of Health and Human Services’] HHS’s strategy for addressing NAS.”

Neonatal abstinence syndrome has become an area of concern for Sg2 clients and other hospitals around the country. Learn the steps health systems can take to address this issue in the Sg2 FAQ: Building a Neonatal Abstinence Syndrome System of CARE.

  • Share
  • Follow Sg2 on Facebook
  • Follow Sg2 on Twitter
  • Connect with Sg2 on LinkedIn
"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Facebook Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube